Related Experiment Video
Updated: Aug 2, 2026
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma
Ingo K Mellinghoff1, Timothy F Cloughesy2
1Department of Neurology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY.
Abstract:
The process of developing cancer therapies is well established and has enabled the incorporation of many new drugs and classes of agents into the standard of care for common cancers. Clinical drug development is fundamentally different for rare and difficult-to-treat solid tumors, such as glioma or pancreatic cancer. The failure to develop effective new agents for the latter diseases has discouraged the development of therapeutics for these cancers. Using glioma as an example, we describe a process toward obtaining more reliable early-stage signals of drug activity and a process toward translating those signals into clinical benefits with more efficient late-stage development. If linked together, these processes should increase the likelihood of benefit in late-stage settings at a lower cost and encourage more drug development for patients with rare and difficult-to-treat cancers.
Insights
Developing new cancer therapies for rare solid tumors like glioma is challenging. This study proposes improved early-stage drug signaling and efficient late-stage development to increase treatment success and encourage research.
Area of Science:
- Oncology
- Drug Development
- Translational Medicine
Background:
- Established cancer therapy development processes are successful for common cancers.
- Rare and difficult-to-treat solid tumors, such as glioma, face significant challenges in therapeutic development.
- Past failures have discouraged investment in novel treatments for these aggressive cancers.
Purpose of the Study:
- To outline a novel process for generating reliable early-stage drug activity signals.
- To describe a method for translating early signals into clinical benefits through efficient late-stage development.
- To encourage further drug development for rare and difficult-to-treat cancers.
Main Methods:
- Utilizing glioma as a model for rare solid tumors.
- Implementing a strategy for more dependable early-stage assessment of drug efficacy.
- Designing a streamlined approach for efficient late-stage clinical trials.
Main Results:
- The proposed integrated process aims to enhance the reliability of early drug signals.
- Efficient late-stage development is expected to translate early signals into demonstrable clinical benefits.
- This approach is projected to lower costs associated with drug development.
Conclusions:
- Linking reliable early-stage signaling with efficient late-stage development can improve patient outcomes.
- This strategy is anticipated to revitalize drug development efforts for challenging cancers.
- Increased success rates and reduced costs may encourage more investment in therapies for rare and difficult-to-treat solid tumors.
